Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil TDS versus sustained-release morphine in chronic cancer pain
2010-023207-10Phase 2Terminated
- Sponsor
- Hameln rds
- Start
- Jan 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cancer pain comparing Sufentanil TDS with Oral sustained-release morphine sulfate (2 arms). Primary endpoint: Daily rescue analgesia consumption during maintenance period. Started Jan 2011; status: terminated.
02
Drugs
sufentanilmorphine
03
Conditions
cancer pain
Beyond the preview
Go deeper on 2010-023207-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023207-10.